emjreviews.com16d
Treatment Strategies and Sequencing After Endocrine Therapy Plus CDK4/6 Inhibitors in Patients with ER+/HER2- Advanced/Metastatic Breast Cancer
2-5 Median PFS (mPFS) in the PALOMA-2 (palbociclib plus letrozole), MONALEESA-2 (ribociclib plus letrozole), MONALEESA-7 (ribociclib plus ET), and MONARCH-3 (abemaciclib plus non-steroidal AI) trials ...
The Financial Express20d
NCCN Guidelines recognises Novartis’ ribociclib as Category 1 preferred breast cancer adjuvant treatment
Recommendation comes after recent FDA approval and positive CHMP Opinion for ribociclib (Kisqali) to help reduce the risk of recurrence in EBC. (Image Credits: Pexels) The NCCN Clinical Practice ...
Fox 44 Waco News21d
Novartis ribociclib (Kisqali®) recognized as Category
EAST HANOVER, N.J., Oct. 24, 2024 /PRNewswire/ -- This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) for breast cancer were updated to recommend ribociclib (Kisqali ®) ...
MedPage Today22d
Alessandro Santin, MD, on a Promising ADC for Refractory Endometrial Cancer
Other agents that have been evaluated in recurrent/advanced endometrial cancer in the post-platinum setting include bevacizumab, letrozole plus everolimus, trastuzumab deruxtecan (for HER2+ cancer ...
BioSpace24d
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
Kisqali ® (ribociclib) is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 ...
Yahoo Finance27d
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing ...
Le Lézard27d
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
will be eligible for adjuvant treatment with Kisqali ® (ribociclib) in combination with an aromatase inhibitor 1 Recommendation is based on the Phase III NATALEE trial, where Kisqali added to ...
Mena FN27d
Novartis Receives Positive CHMP Opinion For Kisqali® To Help Reduce Risk Of Recurrence In People With HR+/HER2- Early Breast Cancer
Ribociclib plus Endocrine Therapy in Early Breast Cancer ... from the Phase III MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with HR+/HER2− advanced breast ...